SPARC broadens rights R&D funding amid unpredictability

Sun Pharma Advanced Research Company (SPARC) has proposed revised plans to deploy the balance of Rs965.87 million ($17.9 million) remaining from a rights issue, including for clinical trials of "equally promising" products such as its lead steroid for allergic rhinitis S0597 and a latanoprost plus timolol ophthalmic combination.